Medica Group announces Barbara Moorhouse to its Board as Senior Independent Director

– UK, Hastings –  Medica Group Plc (LON: MGP), the market leader in the provision of teleradiology services in the UK and Ireland, today announced the appointment of Barbara Moorhouse to its Board of Medica as a Non-Executive Director on 1 July 2021.

Barbara will serve as the Senior Independent Director and Chair of the Audit Committee.

“We are delighted to have someone of Barbara’s expertise and stature join the Board of Medica. Barbara is a seasoned Non-Executive Director and brings significant experience from both the private and public sectors. Coupled with her extensive background in the most senior of finance positions in large scale, highly complex and fast-growing organisations, Barbara will further strengthen Medica’s Board. I very much look forward to working with her.” said Board Chairman, Roy Davis.

About Barbara Moorhouse

Barbara has extensive business and management experience in the private, public and regulated sectors. In the private sector Barbara has held a series of strategic, commercial and finance roles, including being CFO for two international listed IT companies – Kewill Systems plc and Scala Business Solutions NV, Group Finance Director at Morgan Sindall plc, and Regulatory Director at South West Water.

In the public sector, she has been Director General at the Ministry of Justice and the Department for Transport and COO at Westminster City Council.

Barbara has been a Trustee and Chair of the Audit Committee for Guy’s & St Thomas’ Charity and a Non-Executive Director of the NHS West Hampshire Clinical Commissioning Group. She is Non-Executive Director at Balfour Beatty plc, Non-Executive Director and Chair of the Audit Committee at Aptitude Software Group plc and Chair of the Rail Safety & Standards Board. Barbara is currently Non-Executive Director at Agility Trains (East) Ltd, but is stepping down this month having been on the board since 2015.

Barbara Moorhouse said: “I am very pleased to be joining the Board of such an exciting and rapidly-growing company with a compelling strategy in place. I am looking forward to engaging with the Board and the management team and using my expertise to help implement this strategy.”

About Medica Group PLC

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.

The Company currently offers two primary services to hospital radiology departments:

  • NightHawk – urgent reporting service
  • Elective – includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

These services are underpinned by Medica’s bespoke, secure IT platform that provides market-leading linkage between a hospital’s Radiology Information System and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.

Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.